Daratumumab-(225)Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors

Daratumumab is an anti-CD38 directed monoclonal antibody approved for the treatment of multiple myeloma (MM) and functions primarily via Fc-mediated effector mechanisms such as complement-dependent cytotoxicity (CDC), antibody-dependent cell cytotoxicity (ADCC), antibody-dependent cellular phagocyto...

Descripción completa

Detalles Bibliográficos
Autores principales: Dawicki, Wojciech, Allen, Kevin J.H., Jiao, Rubin, Malo, Mackenzie E., Helal, Muath, Berger, Mark S., Ludwig, Dale L., Dadachova, Ekaterina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682347/
https://www.ncbi.nlm.nih.gov/pubmed/31413916
http://dx.doi.org/10.1080/2162402X.2019.1607673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682347/
https://www.ncbi.nlm.nih.gov/pubmed/31413916
http://dx.doi.org/10.1080/2162402X.2019.1607673

Ejemplares similares